Migraine is a severe, painful headache that is often preceded or accompanied by warning signs such as flashes of light, blind spots, tingling in the arms and legs, nausea, vomiting, and increased sensitivity to light and sound. The excruciating pain that migraines bring can last for hours or even days.
 |
| Photo grab from Cefaly website |
The main aspects of treatment includes trigger avoidance, acute symptomatic control, and pharmacological prevention. Medications are more effective when used earlier in an attack. However, frequent use of medications may result in medication overuse headache, in which the headaches become more severe and more frequent. This condition may occur with triptans, ergotamines, and analgesics, especially narcotic analgesics. Due to these concerns simple analgesics are recommended to be used less than three days per week at most.
Medical devices, such as neurostimulators, have some advantages in migraine prevention, mainly when common anti-migraine medications are contraindicated or in case of medication overuse. A transcutaneous electrical nerve stimulation device is approved in the United States for the prevention of migraine and for the treatment of intractable chronic migraines with encouraging results for severe cases.
Cefaly is a CE (Conformité Européene) and ISO (International Organization for Standardization) certified transcutaneous electrical nerve stimulation medical device designed to treat and prevent migraine headaches. This device can considerably reduce or replace the consumption of side effect producing medications. The device is the first cranial analgesic electrotherapeutic device to acquire ISO medical certification proven effective on migraine pain with no side effects.
Neurostimulation of the trigeminal nerve with Cefaly produces a relaxing effect. Regular repetition of this relaxing effect helps reduce the number of attacks of headache and migraine.
Cefaly is designed and developed in accordance with the strictest quality standards eliminating all possible short-term and long-term dangers.
More importantly, Cefaly is backed up by randomized controlled clinical trials such as a double blind clinical trial demonstrating its sedative effects on the central nervous system, efficient reduction of migraine attacks via a multicenter placebo controlled clinical trial and a prospective study of more than 2,000 patients confirming its efficacy and safety for migraine treatment.
For more information on Cefaly, you may contact JCS Pharmaceuticals Inc. at (02)9001610 / (02)9001613.
Comments
Post a Comment